# Delcath Systems, Inc.: overview DCTH · Nasdaq · CIK 872912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dcth.md) · [Financials](/companies/dcth/financials.md) · [Filings](/companies/dcth/filings.md) · [Insiders](/companies/dcth/insiders.md) Latest reported revenue: [$29.1m](/filings/0001628280-26-053956.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053956). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.2](/filings/0001628280-25-048558.md) | [15.1 d](/filings/0001628280-26-012019.md) | [19.8](/filings/0001628280-26-031751.md) | [24.2](/filings/0001628280-26-053956.md) | [20.6](/filings/0001628280-25-048558.md) | [20.7 d](/filings/0001628280-26-012019.md) | [25.0](/filings/0001628280-26-031751.md) | [29.1](/filings/0001628280-26-053956.md) | | Gross margin | % | [85.4%](/filings/0001628280-25-048558.md) | [85.9% d](/filings/0001628280-26-012019.md) | [85.6%](/filings/0001628280-26-031751.md) | [86.3%](/filings/0001628280-26-053956.md) | [87.2%](/filings/0001628280-25-048558.md) | [85.5% d](/filings/0001628280-26-012019.md) | [85.1%](/filings/0001628280-26-031751.md) | [89.8%](/filings/0001628280-26-053956.md) | | Operating margin | % | [(11.2%)](/filings/0001628280-25-048558.md) | [20.1% d](/filings/0001628280-26-012019.md) | [3.2%](/filings/0001628280-26-031751.md) | [10.7%](/filings/0001628280-26-053956.md) | [(1.9%)](/filings/0001628280-25-048558.md) | [(10.5%) d](/filings/0001628280-26-012019.md) | [(6.5%)](/filings/0001628280-26-031751.md) | [8.2%](/filings/0001628280-26-053956.md) | | Net margin | % | [16.6%](/filings/0001628280-25-048558.md) | [(22.5%) d](/filings/0001628280-26-012019.md) | [5.4%](/filings/0001628280-26-053956.md) | [11.2%](/filings/0001628280-26-053956.md) | [4.0%](/filings/0001628280-25-048558.md) | [(9.1%) d](/filings/0001628280-26-012019.md) | [(4.3%)](/filings/0001628280-26-053956.md) | [9.2%](/filings/0001628280-26-053956.md) | | Diluted EPS | $ per share | [0.06](/filings/0001628280-25-048558.md) | not reported | [0.03](/filings/0001628280-26-031751.md) | [0.07](/filings/0001628280-26-053956.md) | [0.02](/filings/0001628280-25-048558.md) | not reported | [(0.03)](/filings/0001628280-26-031751.md) | [0.07](/filings/0001628280-26-053956.md) | | Free cash flow | $m | [(3.9) d](/filings/0001628280-25-048558.md) | [(1.2) d](/filings/0001628280-26-012019.md) | [2.1](/filings/0001628280-26-031751.md) | [6.9 d](/filings/0001628280-26-053956.md) | [4.3 d](/filings/0001628280-25-048558.md) | [7.7 d](/filings/0001628280-26-012019.md) | [0.3](/filings/0001628280-26-031751.md) | [5.2 d](/filings/0001628280-26-053956.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.6](/filings/0001193125-23-079836.md) | [2.7](/filings/0001628280-24-013008.md) | [2.1](/filings/0001628280-25-010797.md) | [37.2](/filings/0001628280-26-012019.md) | [85.2](/filings/0001628280-26-012019.md) | | Gross margin | % | [81.1%](/filings/0001193125-23-079836.md) | [74.8%](/filings/0001628280-24-013008.md) | [69.2%](/filings/0001628280-25-010797.md) | [83.4%](/filings/0001628280-26-012019.md) | [86.2%](/filings/0001628280-26-012019.md) | | Operating margin | % | [(690.0%)](/filings/0001193125-23-079836.md) | [(1245.1%)](/filings/0001628280-24-013008.md) | [(1849.0%)](/filings/0001628280-25-010797.md) | [(33.4%)](/filings/0001628280-26-012019.md) | [0.8%](/filings/0001628280-26-012019.md) | | Net margin | % | [(721.5%)](/filings/0001193125-23-079836.md) | [(1342.7%)](/filings/0001628280-24-013008.md) | [(2308.9%)](/filings/0001628280-25-010797.md) | [(70.9%)](/filings/0001628280-26-012019.md) | [3.2%](/filings/0001628280-26-012019.md) | | Diluted EPS | $ per share | [(3.59)](/filings/0001193125-23-079836.md) | [(4.12)](/filings/0001628280-24-013008.md) | [(2.94)](/filings/0001628280-25-010797.md) | [(0.93)](/filings/0001628280-26-012019.md) | [0.07](/filings/0001628280-26-012019.md) | | Free cash flow | $m | [(22.7)](/filings/0001193125-23-079836.md) | [(25.2)](/filings/0001628280-24-013008.md) | [(31.3)](/filings/0001628280-25-010797.md) | [(19.2)](/filings/0001628280-26-012019.md) | [21.0](/filings/0001628280-26-012019.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dcth/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $41.6m | 3,300,389 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $34.1m | 2,706,802 | | Added +922,336 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $15.4m | 1,221,247 | | Reduced −108,041 | | [Propel Bio Management, LLC](/funds/1969764.md) | 2026-06-30 | $11.0m | 871,460 | | Reduced −108,238 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.2m | 733,115 | | Added +41,084 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $8.6m | 679,280 | | Added +14,852 | | [ALGERT GLOBAL LLC](/funds/1275218.md) | 2026-06-30 | $7.3m | 580,708 | | Added +434,975 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $7.1m | 566,371 | | Reduced −21,684 | | [Divisadero Street Capital Management, LP](/funds/1901865.md) | 2026-06-30 | $6.3m | 499,796 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $5.1m | 407,983 | | Added +22,459 | ## Recent filings [All 1,186 filings](/companies/dcth/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 15:41 ET | [SCHEDULE 13D/A](/filings/0001622627-26-000027.md) | Ownership report, active investor, amended | 0001622627-26-000027 | | 2026-08-14 | 08:09 ET | [8-K](/filings/0001193125-26-350536.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-350536 | | 2026-08-06 | 09:09 ET | [10-Q](/filings/0001628280-26-053956.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053956 | | 2026-08-06 | 08:10 ET | [8-K](/filings/0001628280-26-053902.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053902 | | 2026-05-14 | 08:23 ET | [8-K](/filings/0001193125-26-222899.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-222899 | | 2026-05-07 | 09:09 ET | [10-Q](/filings/0001628280-26-031751.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031751 | | 2026-05-07 | 08:12 ET | [8-K](/filings/0001628280-26-031725.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031725 | | 2026-04-02 | 08:52 ET | [DEF 14A](/filings/0001628280-26-022948.md) | Proxy statement, period 2026-05-13 | 0001628280-26-022948 | | 2026-03-03 | 16:48 ET | [8-K](/filings/0001193125-26-088527.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-088527 | | 2026-02-26 | 09:15 ET | [10-K](/filings/0001628280-26-012019.md) | Annual report, period 2025-12-31 | 0001628280-26-012019 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012019.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9cb9d248-e51b-451b-810c-0ce215151de9) ## About the filer - CIK: 872912 - Tickers: DCTH - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:12 ET. No prices; not investment advice.